Key statistics
On Friday, Acumen Pharmaceuticals Inc (ABOS:NSQ) closed at 2.51, -17.70% below its 52-week high of 3.05, set on Jan 28, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.39 |
|---|---|
| High | 2.65 |
| Low | 2.39 |
| Bid | 2.51 |
| Offer | 2.65 |
| Previous close | 2.39 |
| Average volume | 410.62k |
|---|---|
| Shares outstanding | 60.57m |
| Free float | 56.05m |
| P/E (TTM) | -- |
| Market cap | 144.77m USD |
| EPS (TTM) | -2.21 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
- Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
- Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
- Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
- Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
- Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
- Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
More ▼
